Zydus Cadila,has received final approval from US health regulator for marketing capsules, which are used in treating overactive bladder with symptoms like urinary frequency.
In a BSE filing it stated that, it has received approval from the US Food and Drug Administration (USFDA), to market the fesoterodine fumarate extended release capsules in strengths of 4 mg and 8 mg.
It will be manufacturing the drug at the group’s formulations manufacturing facility in Moraiya, Ahemdabad.
